# Prelude Therapeutics Inc: financial statements, quarterly

PRLD · Nasdaq · CIK 1678660 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prld.md) · [Financials](/companies/prld/financials.md) · [Filings](/companies/prld/filings.md) · [Insiders](/companies/prld/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prld/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [3.0](/filings/0001193125-25-275887.md) | [4.0 d](/filings/0001193125-26-099428.md) | [0.0](/filings/0001193125-26-218173.md) | [0.0](/filings/0001193125-26-343475.md) | [6.5](/filings/0001193125-25-275887.md) | [5.6 d](/filings/0001193125-26-099428.md) | [4.6](/filings/0001193125-26-218173.md) | [5.7](/filings/0001193125-26-343475.md) |
| Research and development | $m | [26.3](/filings/0000950170-24-122377.md) | [30.3 d](/filings/0000950170-25-035921.md) | [27.4](/filings/0000950170-25-064566.md) | [29.5](/filings/0000950170-25-108417.md) | [29.5](/filings/0001193125-25-275887.md) | [31.6 d](/filings/0001193125-26-099428.md) | [28.8](/filings/0001193125-26-218173.md) | [25.8](/filings/0001193125-26-343475.md) | [21.7](/filings/0001193125-25-275887.md) | [18.0 d](/filings/0001193125-26-099428.md) | [13.6](/filings/0001193125-26-218173.md) | [16.1](/filings/0001193125-26-343475.md) |
| Operating income | $m | [(33.4)](/filings/0000950170-24-122377.md) | [(37.4) d](/filings/0000950170-25-035921.md) | [(34.3)](/filings/0000950170-25-064566.md) | [(37.2)](/filings/0000950170-25-108417.md) | [(34.4)](/filings/0001193125-25-275887.md) | [(33.8) d](/filings/0001193125-26-099428.md) | [(34.6)](/filings/0001193125-26-218173.md) | [(32.2)](/filings/0001193125-26-343475.md) | [(20.4)](/filings/0001193125-25-275887.md) | [(17.3) d](/filings/0001193125-26-099428.md) | [(14.2)](/filings/0001193125-26-218173.md) | [(15.5)](/filings/0001193125-26-343475.md) |
| Net income | $m | [(30.6)](/filings/0000950170-24-122377.md) | [(33.1) d](/filings/0000950170-25-035921.md) | [(31.4)](/filings/0001193125-25-275887.md) | [(34.7)](/filings/0001193125-25-275887.md) | [(32.3)](/filings/0001193125-25-275887.md) | [(28.7) d](/filings/0001193125-26-099428.md) | [(32.1)](/filings/0001193125-26-343475.md) | [(31.2)](/filings/0001193125-26-343475.md) | [(19.7)](/filings/0001193125-25-275887.md) | [(16.5) d](/filings/0001193125-26-099428.md) | [(10.4)](/filings/0001193125-26-343475.md) | [(13.9)](/filings/0001193125-26-343475.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0000950170-24-122377.md) | not reported | [(0.42)](/filings/0000950170-25-064566.md) | [(0.46)](/filings/0000950170-25-108417.md) | [(0.43)](/filings/0001193125-25-275887.md) | not reported | [(0.42)](/filings/0001193125-26-218173.md) | [(0.41)](/filings/0001193125-26-343475.md) | [(0.26)](/filings/0001193125-25-275887.md) | not reported | [(0.13)](/filings/0001193125-26-218173.md) | [(0.14)](/filings/0001193125-26-343475.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0000950170-24-122377.md) | not reported | [(0.42)](/filings/0000950170-25-064566.md) | [(0.46)](/filings/0000950170-25-108417.md) | [(0.43)](/filings/0001193125-25-275887.md) | not reported | [(0.42)](/filings/0001193125-26-218173.md) | [(0.41)](/filings/0001193125-26-343475.md) | [(0.26)](/filings/0001193125-25-275887.md) | not reported | [(0.13)](/filings/0001193125-26-218173.md) | [(0.14)](/filings/0001193125-26-343475.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [15.9](/filings/0000950170-23-057523.md) | [25.3](/filings/0000950170-25-035921.md) | [24.7](/filings/0000950170-24-053940.md) | [27.8](/filings/0000950170-24-095065.md) | [11.1](/filings/0000950170-24-122377.md) | [12.5](/filings/0001193125-26-099428.md) | [40.3](/filings/0000950170-25-064566.md) | [25.8](/filings/0000950170-25-108417.md) | [47.5](/filings/0001193125-25-275887.md) | [35.3](/filings/0001193125-26-343475.md) | [21.8](/filings/0001193125-26-218173.md) | [26.3](/filings/0001193125-26-343475.md) |
| Current assets | $m | [235](/filings/0000950170-23-057523.md) | [236](/filings/0000950170-25-035921.md) | [205](/filings/0000950170-24-053940.md) | [183](/filings/0000950170-24-095065.md) | [156](/filings/0000950170-24-122377.md) | [136](/filings/0001193125-26-099428.md) | [102](/filings/0000950170-25-064566.md) | [76.9](/filings/0000950170-25-108417.md) | [58.3](/filings/0001193125-25-275887.md) | [106](/filings/0001193125-26-343475.md) | [84.6](/filings/0001193125-26-218173.md) | [155](/filings/0001193125-26-343475.md) |
| Total assets | $m | [259](/filings/0000950170-23-057523.md) | [278](/filings/0000950170-25-035921.md) | [247](/filings/0000950170-24-053940.md) | [224](/filings/0000950170-24-095065.md) | [197](/filings/0000950170-24-122377.md) | [176](/filings/0001193125-26-099428.md) | [141](/filings/0000950170-25-064566.md) | [115](/filings/0000950170-25-108417.md) | [94.8](/filings/0001193125-25-275887.md) | [141](/filings/0001193125-26-343475.md) | [120](/filings/0001193125-26-218173.md) | [189](/filings/0001193125-26-343475.md) |
| Current liabilities | $m | [16.9](/filings/0000950170-23-057523.md) | [21.8](/filings/0000950170-25-035921.md) | [17.6](/filings/0000950170-24-053940.md) | [23.3](/filings/0000950170-24-095065.md) | [22.2](/filings/0000950170-24-122377.md) | [25.6](/filings/0001193125-26-099428.md) | [19.8](/filings/0000950170-25-064566.md) | [20.9](/filings/0000950170-25-108417.md) | [18.2](/filings/0001193125-25-275887.md) | [53.0](/filings/0001193125-26-343475.md) | [41.7](/filings/0001193125-26-218173.md) | [38.0](/filings/0001193125-26-343475.md) |
| Total liabilities | $m | [20.3](/filings/0000950170-23-057523.md) | [40.6](/filings/0000950170-25-035921.md) | [36.4](/filings/0000950170-24-053940.md) | [42.0](/filings/0000950170-24-095065.md) | [40.8](/filings/0000950170-24-122377.md) | [44.1](/filings/0001193125-26-099428.md) | [38.1](/filings/0000950170-25-064566.md) | [39.1](/filings/0000950170-25-108417.md) | [36.2](/filings/0001193125-25-275887.md) | [72.7](/filings/0001193125-26-343475.md) | [59.5](/filings/0001193125-26-218173.md) | [55.6](/filings/0001193125-26-343475.md) |
| Shareholders' equity | $m | [238](/filings/0000950170-24-122377.md) | [237](/filings/0001193125-26-099428.md) | [211](/filings/0001193125-25-275887.md) | [182](/filings/0001193125-25-275887.md) | [156](/filings/0001193125-25-275887.md) | [131](/filings/0001193125-26-343475.md) | [103](/filings/0001193125-26-343475.md) | [75.8](/filings/0001193125-26-343475.md) | [58.5](/filings/0001193125-25-275887.md) | [68.6](/filings/0001193125-26-343475.md) | [60.2](/filings/0001193125-26-343475.md) | [134](/filings/0001193125-26-343475.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.7) d](/filings/0000950170-24-122377.md) | [(23.6) d](/filings/0000950170-25-035921.md) | [(31.8)](/filings/0000950170-25-064566.md) | [(23.1) d](/filings/0000950170-25-108417.md) | [(27.3) d](/filings/0001193125-25-275887.md) | [(20.7) d](/filings/0001193125-26-099428.md) | [(34.2)](/filings/0001193125-26-218173.md) | [(26.1) d](/filings/0001193125-26-343475.md) | [(19.1) d](/filings/0001193125-25-275887.md) | [23.1 d](/filings/0001193125-26-099428.md) | [(21.7)](/filings/0001193125-26-218173.md) | [(15.6) d](/filings/0001193125-26-343475.md) |
| Capital expenditure | $m | [0.6 d](/filings/0000950170-24-122377.md) | [1.1 d](/filings/0000950170-25-035921.md) | [0.3](/filings/0000950170-25-064566.md) | [0.4 d](/filings/0000950170-25-108417.md) | [0.1 d](/filings/0001193125-25-275887.md) | [0.1 d](/filings/0001193125-26-099428.md) | [0.0](/filings/0001193125-26-218173.md) | [0.0 d](/filings/0001193125-26-343475.md) | [0.0 d](/filings/0001193125-25-275887.md) | [0.0 d](/filings/0001193125-26-099428.md) | [0.0](/filings/0001193125-26-218173.md) | [0.0 d](/filings/0001193125-26-343475.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.4](/filings/0000950170-23-057523.md) | [47.7](/filings/0000950170-24-053940.md) | [56.2](/filings/0000950170-24-095065.md) | [67.6](/filings/0000950170-24-122377.md) | [75.7](/filings/0000950170-25-064566.md) | [75.8](/filings/0000950170-25-108417.md) | [75.9](/filings/0001193125-25-275887.md) | [76.0](/filings/0001193125-26-218173.md) | [76.0](/filings/0001193125-26-343475.md) | [76.1](/filings/0001193125-25-275887.md) | [82.5](/filings/0001193125-26-218173.md) | [98.4](/filings/0001193125-26-343475.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 79,803,485 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343475.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.